Myriad Prolaris Test Data Published
Analysis based on 6 articles · First reported Jul 02, 2026 · Last updated Jul 02, 2026
The positive data from the meta-analysis of the Prolaris Biopsy Test is likely to increase investor confidence in Myriad Genetics, potentially leading to a rise in its stock price. Enhanced adoption of the test could also boost the company's revenue and market share in the molecular diagnostics sector.
Myriad Genetics announced new data from the largest individual-patient-data meta-analysis of its Prolaris Biopsy Test. The study, published in Clinical Genitourinary Cancer, involved over 8,000 patients and demonstrated that the Prolaris Biopsy Test provides significant prognostic information beyond conventional clinical risk categories for patients with localized prostate cancer. This evidence supports the test's role in risk stratification, helping clinicians and patients make informed decisions regarding initial prostate cancer management, including active surveillance, definitive therapy, or treatment escalation. Steven Monda, a study author from the University of Michigan Medicine, highlighted the test's utility, especially for low-risk patients.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard